ストックスクリーナーアプリを入手
48.54
10.77%
4.72
プレマーケット:
48.68
0.14
+0.29%
前日終値:
$43.82
開ける：
$43.66
24時間の取引高:
2.88M
Relative Volume:
2.15
時価総額：
$3.90B
収益：
$541.74M
当期純損益:
$88.01M
株価収益率:
44.69
EPS:
1.0862
ネットキャッシュフロー:
$155.34M
1週間 パフォーマンス:
+19.65%
1か月 パフォーマンス:
+17.05%
6か月 パフォーマンス:
+47.36%
1年 パフォーマンス:
+48.53%
1日の値動き範囲:
$43.51
$48.95
1週間の範囲:
$39.40
$48.95
52週間の値動き範囲:
$29.45
$60.91
Veracyte Inc Stock (VCYT) Company Profile
名前
Veracyte Inc
セクター
電話
(650) 243-6300
住所
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, A, IQV
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
48.54 | 3.90B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | Jefferies | Buy |
| 2025-12-02 | 再開されました | Morgan Stanley | Underweight |
| 2025-10-20 | 開始されました | Canaccord Genuity | Hold |
| 2025-03-20 | 開始されました | Craig Hallum | Buy |
| 2024-12-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-16 | 開始されました | UBS | Buy |
| 2024-10-10 | 開始されました | Guggenheim | Buy |
| 2024-02-23 | 繰り返されました | Needham | Buy |
| 2023-01-18 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-11-18 | 再開されました | Goldman | Buy |
| 2021-06-15 | 開始されました | Raymond James | Outperform |
| 2021-02-18 | 再開されました | Needham | Buy |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2019-07-31 | 開始されました | Lake Street | Buy |
| 2019-07-02 | 開始されました | Needham | Buy |
| 2018-11-29 | ダウングレード | Janney | Buy → Neutral |
| 2018-10-31 | アップグレード | Janney | Neutral → Buy |
| 2017-11-07 | ダウングレード | Janney | Buy → Neutral |
| 2017-11-07 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 再開されました | BTIG Research | Buy |
| 2016-11-14 | 再開されました | Leerink Partners | Outperform |
| 2015-12-18 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-11 | 繰り返されました | Leerink Partners | Outperform |
| 2013-11-26 | 開始されました | William Blair | Outperform |
すべてを表示
Veracyte Inc (VCYT) 最新ニュース
Veracyte stock rises 10.77 percent toward its yearly high - AD HOC NEWS
Is Veracyte Inc (VCYT) Overvalued After 10.8% Rally? GF Value Sa - gurufocus.com
A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares. - Stock Titan
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Understanding Momentum Shifts in (VCYT) - Stock Traders Daily
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing - Zacks Investment Research
Veracyte global chief commercial off. John Leite sells $160,600 stock By Investing.com - Investing.com South Africa
Insider Sell: Global Chief Commercial Officer John Leite Sells 4 - gurufocus.com
Form 4 Veracyte Inc For: 23 September By Investing.com - Investing.com Australia
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - TradingView
A Look at Veracyte Inc (VCYT) After 4.4% Gain -- GF Value $39.14 vs Price $41.52 - gurufocus.com
Veracyte (NASDAQ: VCYT) officer to sell 4,015 shares under Rule 144 - Stock Titan
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow - ChartMill
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Veracyte Inc. (NASDAQ: VCYT) Director Holstein Jens Disposes 5,000 Shares at $40.95 Each - Kalkine Media
Veracyte (VCYT) Dropped, But What Is Driving Attention Now? - simplywall.st
Director Jens Holstein Sells 5,000 Shares of Veracyte (VCYT) - gurufocus.com
A Look at Veracyte Inc (VCYT) After 4.1% Decline -- GF Value $39 - gurufocus.com
Veracyte Director Jens Holstein Executes Sale of 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Veracyte (VCYT) director offloads 5,000 shares under plan - Stock Titan
Craig-Hallum Maintains Veracyte(VCYT.US) With Buy Rating - Moomoo
Veracyte Adds Another Stream to Bladder Franchise, UBS Says - marketscreener.com
Veracyte at Morgan Stanley conference: growth, deals and new tests By Investing.com - Investing.com Nigeria
Veracyte at Morgan Stanley conference: growth, deals and new tests - Investing.com
Needham reiterates Veracyte stock rating at Buy on genomics deal By Investing.com - Investing.com Nigeria
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Needham reiterates Veracyte stock rating at Buy on genomics deal - Investing.com
Veracyte acquires Convergent Genomics for up to $180 million By Investing.com - Investing.com Australia
VCYT Looks 5.7% Overvalued on GF Value™ as Insider Selling Persi - GuruFocus
VCYT Looks 5.7% Overvalued on GF Value™ After Convergent Genomics Acquisition - GuruFocus
Veracyte acquires Convergent Genomics for up to $180 million - Investing.com
Veracyte Buys Convergent Genomics - marketscreener.com
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform - marketscreener.com
Press Release: Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio With a Urinary Tumor DNA Testing Platform - Moomoo
Veracyte (NASDAQ: VCYT) director to sell $204,747 in shares - Stock Titan
Veracyte, Inc. acquired Convergent Genomics, Inc for $180 million. - marketscreener.com
Veracyte (VCYT) Gets a Buy from UBS - theglobeandmail.com
Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies - Yahoo Finance
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tel - GuruFocus
VCYT Maintains Buy Rating by UBS -- Price Target Raised to $65 - GuruFocus
UBS Adjusts Price Target on Veracyte to $65 From $52, Keeps Buy Rating - marketscreener.com
Veracyte CFO Rebecca Chambers Forfeits 3,603 Shares at $44.88 and Sells Additional Shares in Early September - Kalkine Media
VERACYTE Executive Leite John Forfeits 3,961 Shares at $44.88 Each (NASDAQ: VCYT) - Kalkine Media
VERACYTE (NASDAQ: VCYT) Officer Jonathan Wygant Forfeits 1,361 Shares at $44.88 Each - Kalkine Media
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline - Eastern Progress
Chief Scientific & Medical Officer Of Veracyte Sold 33% Of Their Shares - simplywall.st
Veracyte CFO Rebecca Chambers sells $157,394 in VCYT shares By Investing.com - Investing.com Australia
Veracyte EVP, general counsel Annie McGuire sells over $140,000 in stock By Investing.com - Investing.com South Africa
Veracyte chief scientific & med officer sells over $564k stock - Investing.com Nigeria
Veracyte EVP, general counsel Annie McGuire sells over $140,000 in stock - Investing.com Nigeria
Veracyte chief scientific & med officer sells over $564k stock By Investing.com - Investing.com South Africa
Veracyte Inc (VCYT) 財務データ
収益
当期純利益
現金流量
EPS
Veracyte Inc (VCYT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Leite John | Global Chief Commercial Off |
Sep 21 '26 |
Sale |
40.00 |
4,015 |
160,600 |
124,329 |
1.54%
1.65%
大文字化:
|
ボリューム (24 時間):